Home Information & Technology IT Software Progesterone Market

Progesterone Market Size, Share & Trends Analysis Report By Type (Natural Progesterone, Synthetic Progesterone), By Modes of Delivery Source: (Injectable, Suspended Form, Oral, Intravaginal, Others), By Application (Regulation of the Menstrual Cycle, Dysfunctional Uterine Bleeding, Endometrial Cancer, Contraception, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Progesterone Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Natural Progesterone
    2. Synthetic Progesterone
  2. Progesterone Market, By Modes of Delivery Source: 2022-2034 (USD MILLION/ Units)
    1. Injectable
    2. Suspended Form
    3. Oral
    4. Intravaginal
    5. Others
  3. Progesterone Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Regulation of the Menstrual Cycle
    2. Dysfunctional Uterine Bleeding
    3. Endometrial Cancer
    4. Contraception
    5. Others
  4. Regional Progesterone Market
    1. North America
      1. North America Progesterone Market By Type 2022-2034 (USD MILLION/ Units)
        1. Natural Progesterone
        2. Synthetic Progesterone
      2. North America Progesterone Market By Modes of Delivery Source: 2022-2034 (USD MILLION/ Units)
        1. Injectable
        2. Suspended Form
        3. Oral
        4. Intravaginal
        5. Others
      3. North America Progesterone Market By Application 2022-2034 (USD MILLION/ Units)
        1. Regulation of the Menstrual Cycle
        2. Dysfunctional Uterine Bleeding
        3. Endometrial Cancer
        4. Contraception
        5. Others
      4. U.S.
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      5. Canada
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
    2. Europe
      1. Europe Progesterone Market By Type 2022-2034 (USD MILLION/ Units)
        1. Natural Progesterone
        2. Synthetic Progesterone
      2. Europe Progesterone Market By Modes of Delivery Source: 2022-2034 (USD MILLION/ Units)
        1. Injectable
        2. Suspended Form
        3. Oral
        4. Intravaginal
        5. Others
      3. Europe Progesterone Market By Application 2022-2034 (USD MILLION/ Units)
        1. Regulation of the Menstrual Cycle
        2. Dysfunctional Uterine Bleeding
        3. Endometrial Cancer
        4. Contraception
        5. Others
      4. U.K.
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      5. Germany
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      6. France
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      7. Spain
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      8. Italy
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      9. Russia
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      10. Nordic
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      11. Benelux
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      12. Rest of Europe
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
    3. APAC
      1. APAC Progesterone Market By Type 2022-2034 (USD MILLION/ Units)
        1. Natural Progesterone
        2. Synthetic Progesterone
      2. APAC Progesterone Market By Modes of Delivery Source: 2022-2034 (USD MILLION/ Units)
        1. Injectable
        2. Suspended Form
        3. Oral
        4. Intravaginal
        5. Others
      3. APAC Progesterone Market By Application 2022-2034 (USD MILLION/ Units)
        1. Regulation of the Menstrual Cycle
        2. Dysfunctional Uterine Bleeding
        3. Endometrial Cancer
        4. Contraception
        5. Others
      4. China
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      5. Korea
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      6. Japan
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      7. India
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      8. Australia
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      9. Singapore
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      10. Taiwan
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      11. South East Asia
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      12. Rest of Asia-Pacific
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
    4. Middle East and Africa
      1. Middle East and Africa Progesterone Market By Type 2022-2034 (USD MILLION/ Units)
        1. Natural Progesterone
        2. Synthetic Progesterone
      2. Middle East and Africa Progesterone Market By Modes of Delivery Source: 2022-2034 (USD MILLION/ Units)
        1. Injectable
        2. Suspended Form
        3. Oral
        4. Intravaginal
        5. Others
      3. Middle East and Africa Progesterone Market By Application 2022-2034 (USD MILLION/ Units)
        1. Regulation of the Menstrual Cycle
        2. Dysfunctional Uterine Bleeding
        3. Endometrial Cancer
        4. Contraception
        5. Others
      4. UAE
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      5. Turkey
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      6. Saudi Arabia
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      7. South Africa
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      8. Egypt
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      9. Nigeria
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      10. Rest of MEA
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
    5. LATAM
      1. LATAM Progesterone Market By Type 2022-2034 (USD MILLION/ Units)
        1. Natural Progesterone
        2. Synthetic Progesterone
      2. LATAM Progesterone Market By Modes of Delivery Source: 2022-2034 (USD MILLION/ Units)
        1. Injectable
        2. Suspended Form
        3. Oral
        4. Intravaginal
        5. Others
      3. LATAM Progesterone Market By Application 2022-2034 (USD MILLION/ Units)
        1. Regulation of the Menstrual Cycle
        2. Dysfunctional Uterine Bleeding
        3. Endometrial Cancer
        4. Contraception
        5. Others
      4. Brazil
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      5. Mexico
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      6. Argentina
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      7. Chile
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      8. Colombia
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
      9. Rest of LATAM
        1. Natural Progesterone
        2. Synthetic Progesterone
        3. Injectable
        4. Suspended Form
        5. Oral
        6. Intravaginal
        7. Others
        8. Regulation of the Menstrual Cycle
        9. Dysfunctional Uterine Bleeding
        10. Endometrial Cancer
        11. Contraception
        12. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.